Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company's VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. VITAS is the provider of hospice services in an industry dominated primarily by small, non-profit, community-based hospices. VITAS provides hospice care to Medicare beneficiaries participating in these managed care programs. A portion of its VITAS business is operated in the state of Florida. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Facilities & Services
- Sub-Industry: Health Care Services
- Symbol: NYSE:CHE
- CUSIP: 16359R10
- Web: www.chemed.com
Capitalization:- Market Cap: $3.07 billion
- Outstanding Shares: 15,991,000
Average Prices:- 50 Day Moving Avg: $193.25
- 200 Day Moving Avg: $196.09
- 52 Week Range: $132.92 - $216.01
P/E:- Trailing P/E Ratio: 47.60
- Foreward P/E Ratio: 21.70
- P/E Growth: 2.32
Sales & Book Value:- Annual Revenue: $1.62 billion
- Price / Sales: 1.89
- Book Value: $28.33 per share
- Price / Book: 6.77
Dividend:- Annual Dividend: $1.12
- Dividend Yield: 0.6%
Profitability:- EBIDTA: $226.52 million
- Net Margins: 4.16%
- Return on Equity: 26.18%
- Return on Assets: 14.62%
Debt:- Debt-to-Equity Ratio: 0.25%
- Current Ratio: 0.58%
- Quick Ratio: 0.56%
Misc:- Average Volume: 100,536 shs.
- Beta: 1.14
- Short Ratio: 14.63
Frequently Asked Questions for Chemed Corp. (NYSE:CHE)
What is Chemed Corp.'s stock symbol?
Chemed Corp. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."
How often does Chemed Corp. pay dividends? What is the dividend yield for Chemed Corp.?
Chemed Corp. declared a quarterly dividend on Friday, August 4th. Stockholders of record on Monday, August 14th will be given a dividend of $0.28 per share on Friday, September 1st. This represents a $1.12 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend is Thursday, August 10th. This is an increase from Chemed Corp.'s previous quarterly dividend of $0.26. View Chemed Corp.'s Dividend History.
How will Chemed Corp.'s stock buyback program work?
Chemed Corp. announced that its Board of Directors has initiated a share repurchase program on Monday, April 10th 2017, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.3% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its stock is undervalued.
How were Chemed Corp.'s earnings last quarter?
Chemed Corp. (NYSE:CHE) issued its quarterly earnings data on Tuesday, July, 25th. The company reported $2.15 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.89 by $0.26. The business earned $415.06 million during the quarter, compared to analysts' expectations of $407.56 million. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The business's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the company earned $1.80 EPS. View Chemed Corp.'s Earnings History.
When will Chemed Corp. make its next earnings announcement?
What guidance has Chemed Corp. issued on next quarter's earnings?
Chemed Corp. updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $8.10-8.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.96.
Where is Chemed Corp.'s stock going? Where will Chemed Corp.'s stock price be in 2017?
2 brokers have issued 1-year target prices for Chemed Corp.'s stock. Their predictions range from $209.00 to $220.00. On average, they expect Chemed Corp.'s share price to reach $214.50 in the next twelve months. View Analyst Ratings for Chemed Corp..
Who are some of Chemed Corp.'s key competitors?
Some companies that are related to Chemed Corp. include NMC Health PLC (NMC), HealthSouth Corporation (HLS), Acadia Healthcare Company (ACHC), Mednax (MD), Molina Healthcare (MOH), Select Medical Holdings Corporation (SEM), LifePoint Health (LPNT), Udg Healthcare PLC (UDG), Tenet Healthcare Corporation (THC), HMS Holdings Corp (HMSY), Community Health Systems (CYH), China Cord Blood Corporation (CO), HealthStream (HSTM), Kindred Healthcare (KND), American Renal Associates Holdings (ARA), Georgia Healthcare Group PLC (GHG), Cambian Group PLC (CMBN) and Concord Medical Services Holdings Limited (CCM).
Who are Chemed Corp.'s key executives?
Chemed Corp.'s management team includes the folowing people:
- George J. Walsh III, Independent Chairman of the Board
- Kevin J. McNamara, President, Chief Executive Officer, Director
- David Patrick Williams, Chief Financial Officer, Executive Vice President
- Spencer S. Lee, Executive Vice President
- Nicholas Michael Westfall, Executive Vice President
- Michael D. Witzeman, Principal Accounting Officer, Controller
- Thomas Charles Hutton, Director
- Joel F. Gemunder, Independent Director
- Patrick P. Grace, Independent Director
- Walter L. Krebs, Independent Director
Who owns Chemed Corp. stock?
Chemed Corp.'s stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.00%), Vanguard Group Inc. (11.45%), Neuberger Berman Group LLC (6.37%), Riverbridge Partners LLC (4.17%), FMR LLC (4.11%) and Acadian Asset Management LLC (3.60%). Company insiders that own Chemed Corp. stock include Arthur V Tucker Jr, David Patrick Williams, Donald E Saunders, George J Walsh III, Kevin J Mcnamara, Patrick P Grace and Spencer S Lee. View Institutional Ownership Trends for Chemed Corp..
Who sold Chemed Corp. stock? Who is selling Chemed Corp. stock?
Chemed Corp.'s stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Investec Asset Management LTD, Riverbridge Partners LLC, Neuberger Berman Group LLC, Gamco Investors INC. ET AL, BTIM Corp., BlackRock Inc. and Fiera Capital Corp. Company insiders that have sold Chemed Corp. stock in the last year include Arthur V Tucker Jr, Donald E Saunders, Kevin J Mcnamara, Patrick P Grace and Spencer S Lee. View Insider Buying and Selling for Chemed Corp..
Who bought Chemed Corp. stock? Who is buying Chemed Corp. stock?
Chemed Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., AJO LP, Old Mutual Global Investors UK Ltd., JPMorgan Chase & Co., Copeland Capital Management LLC and American Century Companies Inc.. Company insiders that have bought Chemed Corp. stock in the last two years include Donald E Saunders and George J Walsh III. View Insider Buying and Selling for Chemed Corp..
How do I buy Chemed Corp. stock?
Shares of Chemed Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chemed Corp.'s stock price today?
One share of Chemed Corp. stock can currently be purchased for approximately $191.86.
MarketBeat Community Rating for Chemed Corp. (NYSE CHE)MarketBeat's community ratings are surveys of what our community members think about Chemed Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Chemed Corp. (NYSE:CHE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $214.50 (11.80% upside) |
Analysts' Ratings History for Chemed Corp. (NYSE:CHE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/1/2017 | Royal Bank Of Canada | Reiterated Rating | Hold | $209.00 | N/A |  |
| 8/28/2017 | KeyCorp | Initiated Coverage | Sector Weight -> Sector Weight | | Low | |
| 7/27/2017 | Oppenheimer Holdings, Inc. | Boost Price Target | Outperform | $200.00 -> $220.00 | Medium | |
| 9/4/2016 | JMP Securities | Reiterated Rating | Hold | | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Chemed Corp. (NYSE:CHE)Earnings History by Quarter for Chemed Corp. (NYSE CHE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | $2.00 | | | | | N/A | |
| 7/25/2017 | Q2 2017 | $1.89 | $2.15 | $407.56 million | $415.06 million | View | N/A | |
| 4/26/2017 | Q1 2017 | $1.78 | $1.82 | $399.75 million | $405.90 million | View | N/A | |
| 2/15/2017 | Q416 | $2.10 | $2.10 | $409.89 million | $403.00 million | View | Listen | |
| 10/26/2016 | Q316 | $1.82 | $1.73 | $270.44 million | $392.61 million | View | Listen | |
| 7/25/2016 | Q216 | $1.72 | $1.80 | $393.50 million | $290.00 million | View | Listen | |
| 4/28/2016 | Q116 | $1.58 | $1.62 | $391.68 million | $390.40 million | View | Listen | |
| 2/17/2016 | Q415 | $1.81 | $1.97 | $390.22 million | $398.60 million | View | Listen | |
| 10/22/2015 | Q315 | $1.61 | $1.78 | $375.95 million | $386.23 million | View | Listen | |
| 7/23/2015 | Q215 | $1.59 | $1.71 | $375.01 million | $382.00 million | View | Listen | |
| 4/28/2015 | Q115 | $1.35 | $1.54 | $370.76 million | $377.00 million | View | Listen | |
| 2/17/2015 | Q414 | $1.65 | $1.80 | $372.54 million | $379.00 million | View | Listen | |
| 10/30/2014 | Q314 | $1.34 | $1.40 | $360.00 million | $358.40 million | View | Listen | |
| 7/23/2014 | Q214 | $1.31 | $1.50 | $363.73 million | $360.18 million | View | Listen | |
| 4/29/2014 | Q114 | $1.23 | $1.32 | $256.77 million | $358.30 million | View | Listen | |
| 10/29/2013 | Q313 | $1.34 | $1.36 | $355.40 million | $340.90 million | View | Listen | |
| 7/18/2013 | Q2 2013 | $1.33 | $1.44 | $368.06 million | $357.00 million | View | Listen | |
| 4/18/2013 | Q1 2013 | $1.29 | $1.38 | $365.08 million | $367.00 million | View | Listen | |
| 2/18/2013 | Q4 2012 | $1.15 | $1.57 | $355.31 million | $369.00 million | View | Listen | |
| 10/29/2012 | Q312 | $1.35 | $1.28 | $360.50 million | $354.00 million | View | N/A | |
| 7/25/2012 | | $1.26 | $1.26 | | | View | N/A | |
| 4/19/2012 | | $1.25 | $1.21 | | | View | N/A | |
| 2/14/2012 | | $1.48 | $1.45 | | | View | N/A | |
| 10/25/2011 | | $1.15 | $1.20 | | | View | N/A | |
| 4/26/2011 | | $0.98 | $1.07 | | | View | N/A | |
| 2/15/2011 | | $1.05 | $0.98 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Chemed Corp. (NYSE:CHE)2017 EPS Consensus Estimate: $7.89
2018 EPS Consensus Estimate: $8.61
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $1.77 | $1.77 | $1.77 |
| Q2 2017 | 1 | $1.89 | $1.89 | $1.89 |
| Q3 2017 | 2 | $1.97 | $2.02 | $2.00 |
| Q4 2017 | 2 | $2.23 | $2.24 | $2.24 |
| Q1 2018 | 1 | $1.95 | $1.95 | $1.95 |
| Q2 2018 | 1 | $2.09 | $2.09 | $2.09 |
| Q3 2018 | 1 | $2.14 | $2.14 | $2.14 |
| Q4 2018 | 1 | $2.43 | $2.43 | $2.43 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Chemed Corp. (NYSE:CHE)| Most Recent Dividend: | 9/1/2017 |
| Annual Dividend: | $1.12 |
| Dividend Yield: | 0.58% |
| Dividend Growth: | 9.60% (3 Year Average) |
| Payout Ratio: | 28.07% (Trailing 12 Months of Earnings)
13.64% (Based on This Year's Estimates)
12.67% (Based on Next Year's Estimates)
|
| Track Record: | 8 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Chemed Corp. (NYSE CHE)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 8/4/2017 | quarterly | $0.28 | 0.57% | 8/10/2017 | 8/14/2017 | 9/1/2017 |
| 5/15/2017 | Quarterly | $0.26 | 0.51% | 5/23/2017 | 5/25/2017 | 6/14/2017 |
| 2/17/2017 | quarterly | $0.26 | 0.59% | 2/23/2017 | 2/27/2017 | 3/20/2017 |
| 11/4/2016 | quarterly | $0.26 | 0.76% | 11/9/2016 | 11/14/2016 | 12/5/2016 |
| 8/5/2016 | quarterly | $0.26 | 0.72% | 8/11/2016 | 8/15/2016 | 9/2/2016 |
| 5/16/2016 | quarterly | $0.24 | 0.76% | 5/24/2016 | 5/26/2016 | 6/15/2016 |
| 2/19/2016 | quarterly | $0.24 | 0.75% | 2/25/2016 | 2/29/2016 | 3/21/2016 |
| 11/6/2015 | quarterly | $0.24 | 0.63% | 11/12/2015 | 11/16/2015 | 12/7/2015 |
| 8/7/2015 | quarterly | $0.24 | 0.63% | 8/13/2015 | 8/17/2015 | 9/4/2015 |
| 5/18/2015 | quarterly | $0.22 | 0.71% | 5/26/2015 | 5/28/2015 | 6/17/2015 |
| 2/20/2015 | quarterly | $0.22 | 0.77% | 2/26/2015 | 3/2/2015 | 3/23/2015 |
| 11/7/2014 | quarterly | $0.22 | 0.81% | 11/13/2014 | 11/17/2014 | 12/8/2014 |
| 8/11/2014 | quarterly | $0.22 | 0.88% | 8/14/2014 | 8/18/2014 | 9/13/2014 |
| 8/8/2014 | quarterly | $0.22 | | 8/14/2014 | 8/18/2014 | 9/3/2014 |
| 5/19/2014 | quarterly | $0.20 | 0.91% | 5/27/2014 | 5/29/2014 | 6/18/2014 |
| 2/21/2014 | quarterly | $0.20 | 0.94% | 2/27/2014 | 3/3/2014 | 3/24/2014 |
| 11/8/2013 | quarterly | $0.20 | 1.13% | 11/14/2013 | 11/18/2013 | 12/9/2013 |
| 8/2/2013 | quarterly | $0.20 | 1.1% | 8/8/2013 | 8/12/2013 | 9/3/2013 |
| 5/20/2013 | quarterly | $0.18 | 1.05% | 5/28/2013 | 5/30/2013 | 6/19/2013 |
| 2/20/2013 | quarterly | $0.18 | 0.92% | 2/28/2013 | 3/4/2013 | 3/22/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Chemed Corp. (NYSE:CHE)Insider Ownership Percentage: 5.32%
Institutional Ownership Percentage: 96.96%
Insider Trades by Quarter for Chemed Corp. (NYSE:CHE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/1/2017 | Spencer S Lee | Insider | Sell | 1,000 | $197.46 | $197,460.00 | |
| 7/28/2017 | Kevin J Mcnamara | Insider | Sell | 15,000 | $201.16 | $3,017,400.00 | |
| 6/26/2017 | George J Walsh III | Director | Buy | 1,000 | $204.56 | $204,560.00 | |
| 5/4/2017 | Donald E Saunders | Director | Buy | 94 | $205.59 | $19,325.46 | |
| 5/3/2017 | Donald E Saunders | Director | Sell | 400 | $204.85 | $81,940.00 | |
| 5/2/2017 | Kevin J Mcnamara | Insider | Sell | 4,000 | $205.11 | $820,440.00 | |
| 5/1/2017 | Spencer S Lee | Insider | Sell | 1,000 | $202.47 | $202,470.00 | |
| 3/3/2017 | Kevin J Mcnamara | Insider | Sell | 7,000 | $181.74 | $1,272,180.00 | |
| 3/2/2017 | Arthur V Tucker Jr | VP | Sell | 2,266 | $181.00 | $410,146.00 | |
| 2/27/2017 | Arthur V Tucker Jr | VP | Sell | 8,878 | $179.21 | $1,591,026.38 | |
| 2/24/2017 | Kevin J Mcnamara | Insider | Sell | 7,000 | $177.63 | $1,243,410.00 | |
| 11/28/2016 | Patrick P Grace | Director | Sell | 400 | $148.53 | $59,412.00 | |
| 11/14/2016 | Donald E Saunders | Director | Sell | 500 | $149.56 | $74,780.00 | |
| 11/14/2016 | Spencer S Lee | Insider | Sell | 4,500 | $150.22 | $675,990.00 | |
| 10/31/2016 | Kevin J Mcnamara | Insider | Sell | 10,000 | $138.40 | $1,384,000.00 | |
| 9/22/2016 | Spencer S Lee | Insider | Sell | 2,000 | $141.67 | $283,340.00 | |
| 8/8/2016 | Donald E Saunders | Director | Sell | 500 | $144.32 | $72,160.00 | |
| 8/5/2016 | Arthur V Tucker Jr | VP | Sell | 4,500 | $144.28 | $649,260.00 | |
| 8/4/2016 | Arthur V Tucker Jr | VP | Sell | 3,089 | $143.88 | $444,445.32 | |
| 8/3/2016 | Kevin J Mcnamara | Insider | Sell | 18,000 | $144.87 | $2,607,660.00 | |
| 5/16/2016 | Donald E Saunders | Director | Buy | 77 | $126.53 | $9,742.81 | |
| 3/21/2016 | Spencer S Lee | EVP | Sell | 24,382 | $132.29 | $3,225,494.78 | |
| 1/27/2016 | Patrick P Grace | Director | Sell | 50 | $138.98 | $6,949.00 | |
| 12/11/2015 | David Patrick Williams | CFO | Sell | 5,000 | $151.72 | $758,600.00 | |
| 11/24/2015 | Spencer S Lee | EVP | Sell | 5,000 | $154.10 | $770,500.00 | |
| 11/6/2015 | Kevin J Mcnamara | CEO | Sell | 6,000 | $157.02 | $942,120.00 | |
| 10/27/2015 | Spencer S. Lee | EVP | Sell | 4,000 | $153.64 | $614,560.00 | |
| 10/26/2015 | Kevin J. Mcnamara | CEO | Sell | 8,000 | $149.04 | $1,192,320.00 | |
| 8/24/2015 | David Patrick Williams | CFO | Sell | 10,000 | $138.09 | $1,380,900.00 | |
| 5/15/2015 | Arthur V Tucker Jr | VP | Sell | 9,000 | $121.00 | $1,089,000.00 | |
| 5/7/2015 | Kevin J Mcnamara | CEO | Sell | 8,000 | $120.82 | $966,560.00 | |
| 3/6/2015 | Spencer S Lee | EVP | Sell | 9,931 | $115.16 | $1,143,653.96 | |
| 3/2/2015 | Timothy S Otoole | EVP | Sell | 10,000 | $117.82 | $1,178,200.00 | |
| 2/27/2015 | Arthur V Tucker Jr | VP | Sell | 7,000 | $116.80 | $817,600.00 | |
| 2/24/2015 | Arthur V Tucker Jr | VP | Sell | 2,685 | $114.35 | $307,029.75 | |
| 2/23/2015 | Spencer S Lee | EVP | Sell | 10,000 | $113.18 | $1,131,800.00 | |
| 2/20/2015 | Kevin J Mcnamara | CEO | Sell | 13,000 | $112.71 | $1,465,230.00 | |
| 11/14/2014 | Timothy S Otoole | EVP | Sell | 5,000 | $106.81 | $534,050.00 | |
| 11/13/2014 | Spencer S Lee | EVP | Sell | 10,000 | $108.38 | $1,083,800.00 | |
| 11/4/2014 | Kevin J Mcnamara | CEO | Sell | 4,000 | $104.13 | $416,520.00 | |
| 9/10/2014 | Spencer S Lee | EVP | Sell | 2,000 | $105.80 | $211,600.00 | |
| 9/8/2014 | David Patrick Williams | CFO | Sell | 5,000 | $105.90 | $529,500.00 | |
| 8/7/2014 | Kevin J Mcnamara | CEO | Sell | 5,000 | $100.05 | $500,250.00 | |
| 7/25/2014 | Arthur V Tucker Jr | VP | Sell | 9,000 | $101.26 | $911,340.00 | |
| 7/25/2014 | Kevin J Mcnamara | CEO | Sell | 10,000 | $101.00 | $1,010,000.00 | |
| 5/15/2014 | Timothy Otoole | EVP | Sell | 9,000 | $87.62 | $788,580.00 | |
| 5/5/2014 | Kevin Mcnamara | CEO | Sell | 5,000 | $85.05 | $425,250.00 | |
| 4/2/2014 | Spencer Lee | EVP | Sell | 2,000 | $90.15 | $180,300.00 | |
| 3/19/2014 | Thomas Hutton | VP | Sell | 2,201 | $88.36 | $194,480.36 | |
| 3/11/2014 | Timothy Otoole | EVP | Sell | 6,000 | $86.60 | $519,600.00 | |
| 3/3/2014 | Kevin Mcnamara | CEO | Sell | 4,000 | $84.47 | $337,880.00 | |
| 2/28/2014 | Arthur Tucker, Jr. | VP | Sell | 9,000 | $85.01 | $765,090.00 | |
| 2/25/2014 | Arthur Tucker, Jr. | VP | Sell | 8,461 | $83.80 | $709,031.80 | |
| 2/20/2014 | Spencer Lee | EVP | Sell | 2,000 | $82.51 | $165,020.00 | |
| 2/19/2014 | Kevin Mcnamara | CEO | Sell | 4,000 | $82.18 | $328,720.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Chemed Corp. (NYSE:CHE)
Latest Headlines for Chemed Corp. (NYSE:CHE)
| Source: |
|
| Date | Headline |
|---|
 | Here's Why You Should Add Chemed (CHE) to Your Portfolio
finance.yahoo.com - September 22 at 4:08 PM |
| Amedisys or Chemed: Which is a Better Investment Choice?
finance.yahoo.com - September 22 at 10:07 AM |
| Why Should Investors Add Amedisys (AMED) to Their Portfolio?
finance.yahoo.com - September 21 at 4:58 PM |
| Here's Why You Should Add Chemed (CHE) to Your Portfolio
finance.yahoo.com - September 21 at 10:45 AM |
| Chemed Getting Closer To Key Technical Measure
finance.yahoo.com - September 18 at 3:41 PM |
 | Chemed Corp. (CHE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - September 18 at 10:16 AM |
| Chemed Corp. (CHE) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 14 at 2:40 AM |
| CVS Health Gains on Pharmacy Services, Retail Remains a Drag
finance.yahoo.com - September 13 at 6:21 PM |
| Chemed Corp. (CHE) Downgraded by Zacks Investment Research
www.americanbankingnews.com - September 13 at 6:04 PM |
| Zacks Investment Research Lowers Chemed Corp. (CHE) to Hold
www.americanbankingnews.com - September 10 at 5:52 PM |
| Analysts Anticipate Chemed Corp. (CHE) Will Announce Earnings of $2.00 Per Share
www.americanbankingnews.com - September 10 at 4:10 PM |
| NuVasive Grows in Pediatric Deformity With New FDA Approval
finance.yahoo.com - September 8 at 5:33 PM |
| Chemed Rides on VITAS Recovery, Robust Roto-Rooter Sales
finance.yahoo.com - September 8 at 5:33 PM |
| Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
finance.yahoo.com - September 7 at 5:16 PM |
| Royal Bank Of Canada Reaffirms Hold Rating for Chemed Corp. (CHE)
www.americanbankingnews.com - September 2 at 6:56 AM |
| Spencer S. Lee Sells 1,000 Shares of Chemed Corp. (CHE) Stock
www.americanbankingnews.com - September 1 at 4:20 PM |
| Comparing Select Medical Holdings Corporation (SEM) and Chemed Corp. (CHE)
www.americanbankingnews.com - September 1 at 12:26 PM |
| Omnova Solutions and Chemed are Zacks Aggressive Growth Rank Buys
finance.yahoo.com - August 31 at 5:02 PM |
| Brokers Issue Forecasts for Chemed Corp.'s Q3 2017 Earnings (CHE)
www.americanbankingnews.com - August 31 at 8:28 AM |
 | Here's Why Chemed (CHE) is a Suitable Growth Pick for Now
www.zacks.com - August 29 at 3:08 AM |
| KeyCorp Initiates Coverage on Chemed Corp. (CHE)
www.americanbankingnews.com - August 28 at 10:28 AM |
| Why Is Chemed (CHE) Down 7.8% Since the Last Earnings Report?
finance.yahoo.com - August 25 at 6:56 PM |
| Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms
finance.yahoo.com - August 25 at 6:56 PM |
| Chemed Co. (CHE) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 23 at 4:46 PM |
| Chemed Co. (CHE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 22 at 3:50 PM |
| Chemed Corp. (CHE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 20 at 2:26 AM |
| ETFs with exposure to Chemed Corp. : August 18, 2017
finance.yahoo.com - August 18 at 5:16 PM |
| See what the IHS Markit Score report has to say about Chemed Corp.
finance.yahoo.com - August 10 at 3:22 AM |
 | Ex-Dividend Reminder: Chemed, CNA Financial and Carlyle Group
www.nasdaq.com - August 8 at 4:54 PM |
| Chemed Corp. :CHE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 7, 2017
finance.yahoo.com - August 7 at 5:35 PM |
| Chemed Corporation Increases Quarterly Dividend 7.7%
finance.yahoo.com - August 4 at 5:24 PM |
| Chemed Corp. (CHE) Plans Dividend of $0.28
www.americanbankingnews.com - August 4 at 2:44 PM |
| Chemed Enters Oversold Territory (CHE)
www.nasdaq.com - August 3 at 6:39 PM |
| Zacks.com featured highlights: Arkema, Nutrisystem, SYNNEX, Ituran Location and Control and Chemed
finance.yahoo.com - August 3 at 6:39 PM |
| Chemed Corp. (NYSE:CHE) Insider Sells $3,017,400.00 in Stock
www.americanbankingnews.com - July 31 at 4:26 PM |
| Chemed Corp. (NYSE:CHE) Given Hold Rating at Royal Bank Of Canada
www.americanbankingnews.com - July 31 at 1:38 PM |
| Chemed Corp. to Post Q3 2017 Earnings of $1.97 Per Share, Oppenheimer Holdings Forecasts (NYSE:CHE)
www.americanbankingnews.com - July 31 at 7:51 AM |
| Chemed Corp. Expected to Post Q4 2017 Earnings of $2.23 Per Share (NYSE:CHE)
www.americanbankingnews.com - July 28 at 4:09 PM |
| Chemed Corp. (CHE) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 28 at 2:09 PM |
| Chemed Corp. (CHE) Price Target Increased to $220.00 by Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 27 at 1:14 PM |
| Edited Transcript of CHE earnings conference call or presentation 26-Jul-17 2:00pm GMT
finance.yahoo.com - July 27 at 3:40 AM |
| Chemed Corp. (CHE) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 26 at 11:59 PM |
| Chemed Corp. (CHE) Cut to C+ at TheStreet
www.americanbankingnews.com - July 26 at 9:52 PM |
| Investor Network: Chemed Corporation to Host Earnings Call
finance.yahoo.com - July 26 at 5:42 PM |
| Comparing American Renal Associates Holdings (ARA) & Chemed Corp. (NYSE:CHE)
www.americanbankingnews.com - July 26 at 8:28 AM |
| Chemed Corp. (CHE) Issues FY17 Earnings Guidance
www.americanbankingnews.com - July 25 at 10:32 PM |
| Chemed Increases Earnings Guidance - Quick Facts
www.nasdaq.com - July 25 at 10:07 PM |
 | BRIEF-Chemed Corp qtrly adjusted diluted eps $2.15
www.reuters.com - July 25 at 10:07 PM |
| Chemed reports 2Q loss
finance.yahoo.com - July 25 at 10:07 PM |
| Chemed Corp. (CHE) Releases Earnings Results, Beats Expectations By $0.26 EPS
www.americanbankingnews.com - July 25 at 9:05 PM |
Chemed Corp. (CHE) Chart for Sunday, September, 24, 2017
